0001188112-12-003535.txt : 20121205 0001188112-12-003535.hdr.sgml : 20121205 20121205114246 ACCESSION NUMBER: 0001188112-12-003535 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121130 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20121205 DATE AS OF CHANGE: 20121205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 002-90539 FILM NUMBER: 121242617 BUSINESS ADDRESS: STREET 1: 25 HEALTH SCIENCES DRIVE STREET 2: SUITE 113 CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631 444 6861 MAIL ADDRESS: STREET 1: 25 HEALTH SCIENCES DRIVE STREET 2: SUITE 113 CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 8-K 1 t75125_8k.htm FORM 8-K t75125_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
 
 
Date of report (Date of earliest event reported): November 30, 2012
 
Applied DNA Sciences, Inc.
 
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction
of Incorporation)
002-90539
(Commission File Number)
59-2262718
(IRS Employer
Identification No.)

 

 
25 Health Sciences Drive, Suite 215
Stony Brook, New York 11790
(Address of Principal Executive Offices) (Zip Code)
 
631-444- 8090
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 40.14d - (b))
   
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e - (c))
 
 
 
 
 
 
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
    (b) On November 30, 2012, Mr. Gerald Catenacci advised the Board of Directors of Applied DNA Sciences, Inc. (the “Company”) that he would not stand for re-election as a director of the Company at the Company’s 2013 Annual Meeting of Stockholders.
 
    (e) On November 30, 2012, the Board of Directors of the Company increased the annual  salary payable to Dr. James A. Hayward, Chairman, President and Chief Executive Officer of the Company, from $225,000 to $350,000. In addition, the Board granted a cash bonus of $150,000 to Dr. Hayward which would be payable upon the closing of an additional $5.5 Million investment by Crede CG II, Ltd. (“Crede”)  agreed to occur on the date a registration statement is declared effective by the Securities and Exchange Commission relating to the resale of shares of Common Stock issued or to be issued to Crede.
 
    On November 30, 2012, the Board of Directors of the Company increased the annual salary payable to Mr. Kurt H. Jensen, Chief Financial Officer of the Company, from $225,000 to $315,000. In addition, the Board granted a cash bonus of $100,000 to Mr. Jensen.
 
    On November 30, 2012, the Board of Directors of the Company granted a cash bonus of $10,000 to Mr. Ming-Hwa Liang, Chief Technology Officer and Secretary of the Company.
 
 
 
 
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Applied DNA Sciences, Inc.
 
(Registrant)
   
   
 
By:
/s/ James A. Hayward                                                                
   
James A. Hayward
Chairman, President and Chief Executive Officer
 
 
    
Date: December 5, 2012